Home > Estrogen/progestogen Receptor & > Medroxyprogesterone acetate

Medroxyprogesterone acetate

醋酸安宫黄体酮,NSC-26386,NSC 26386,NSC26386

Medroxyprogesterone醋酸盐是孕酮受体激动剂，是合成的人激素孕酮变体。

目录号
EY1617
EY1617
纯度
99.23%
99.23%
规格
100 mg
500 mg
原价
430
775
售价
430
775
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Medroxyprogesterone acetate (MPA) is a synthetic progestin and act as a potent progesterone receptor agonist, used to treat abnormal menstruation or irregular vaginal bleeding.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Ciriza I, et al. J Neurobiol,2006, 66(9), 916-928.

    分子式
    C24H34O4    		 分子量
    386.52    		 CAS号
    71-58-9    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    12 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    12 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00830414 Healthy Drug: medroxyprogesterone acetate|Drug: medroxyprogesterone acetate Teva Pharmaceuticals USA Phase 1 2002-04-01 2009-01-26
    NCT01296152 HIV-1 Infection Drug: depo-medroxyprogesterone acetate AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2011-05-01 2015-11-18
    NCT02509767 Contraception Drug: Subcutaneous depot medroxyprogesterone acetate Planned Parenthood Federation of America|Tara Health Foundation|Pfizer Phase 4 2015-08-01 2016-03-05
    NCT00563576 Metrorrhagia Drug: Femring|Drug: DepoProvera  Columbia University 2007-09-01 2012-12-11
    NCT01143207 Contraception Drug: Medroxyprogesterone acetate FHI 360|Eastern Virginia Medical School 2010-05-01 2013-08-05
    NCT02340013 Infertility Drug: Medroxyprogesterone acetate Samuel Lunenfeld Research Institute, Mount Sinai Hospital|University of Toronto Phase 4 2013-07-01 2015-11-11
    NCT00770887 Fertility Procedure: Self administration University of North Carolina, Chapel Hill|Pfizer|Planned Parenthood Federation of America 2010-05-01 2011-08-09
    NCT01461824 Weight Gain|Disorder of Bone Density and Structure, Unspecified|Uterine Bleeding Drug: Depot medroxyprogesterone acetate (DMPA) Nationwide Children's Hospital|Society of Family Planning Phase 3 2011-09-01 2015-07-15
    NCT03018249 Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma Drug: Entinostat|Procedure: Hysterectomy|Other: Laboratory Biomarker Analysis|Drug: Medroxyprogesterone Acetate National Cancer Institute (NCI) Phase 2 2017-08-01 2017-01-31
    NCT01019369 Contraception Drug: Medroxyprogesterone 17-Acetate|Drug: Medroxyprogesterone 17-Acetate Carolyn L. Westhoff|Family Planning Fellowship|Pfizer|Columbia University 2010-03-01 2015-04-14
    NCT00064025 Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer Other: Laboratory Biomarker Analysis|Drug: Medroxyprogesterone|Procedure: Therapeutic Conventional Surgery Gynecologic Oncology Group|National Cancer Institute (NCI) Phase 2 2004-04-01 2016-03-17
    NCT01776203 Dysfunctional Uterine Bleeding Drug: Medroxyprogesterone 17-Acetate Kaiser Permanente Phase 4 2012-01-01 2015-03-10
    NCT02732418 Contraception Drug: Depo-Provera CI|Drug: Depo-subQ 104 FHI 360 Phase 1 2016-10-01 2016-12-22
    NCT01463202 Contraception|Postpartum Depression|Lactation Drug: Depot medroxyprogesterone acetate|Drug: Depot medroxyprogesterone acetate University of Pittsburgh|Society of Family Planning Phase 4 2011-11-01 2017-02-16
    NCT02335203 Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Complex Atypical Endometrial Hyperplasia Drug: Depot medroxyprogesterone acetate|Other: Placebo Women and Infants Hospital of Rhode Island Phase 2 2015-02-01 2016-09-17
    NCT01191203 HIV Drug: Copper IUD|Drug: Depo Medroxyprogesterone acetate Emory University|University of North Carolina|National Institute of Allergy and Infectious Diseases (NIAID) 2010-07-01 2013-10-23
    NCT02449161 Menorrhagia Drug: MPA|Drug: placebo Guy Waddell|CSSS Chicoutimi|Universit de Sherbrooke Phase 3 2015-06-01 2016-05-10
    NCT01594879 Endometrial Cancer Device: MIrena(LNG-IUS), oral MPA Korean Gynecologic Oncology Group Phase 2 2012-01-01 2012-05-08
    NCT01791413 Endometriosis Drug: depot medroxyprogesterone acetate Mahidol University Phase 1|Phase 2 2012-03-01 2013-08-23
    NCT02103764 Dysfunctional Uterine Bleeding Drug: Desogestrel|Drug: Medroxyprogesterone acetate Mahidol University Phase 3 2013-08-01 2015-07-04
    NCT02412436 HIV-1 Infection|Tuberculosis Drug: depot medroxyprogesterone acetate AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2015-09-01 2017-03-20
    NCT00030914 Hot Flashes Drug: medroxyprogesterone|Drug: venlafaxine Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Phase 3 2002-04-01 2016-07-12
    NCT01056042 Endometriosis Drug: intramuscular depot medroxyprogesterone acetate|Drug: ethinyl estradiol 30 micrograms, gestodene 75 micrograms Prince of Songkla University Phase 4 2007-06-01 2014-10-28

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：